Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17152952 | 0.90 | ALDH1A1 (0.45) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL18412514 | 0.89 | L3MBTL1 (0.43) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL17155173 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL17152954 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL17152949 | 0.84 | CTSB (0.44) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL9883952 | 0.83 | ALDH1A1 (0.48) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL18406798 | 0.80 | ALDH1A1 (0.34) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL17152939 | 0.80 | ALDH1A1 (0.59) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL12195291 | 0.79 | KDM4E (0.56) | ALDH1A1LMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL16656263 | 0.79 | KDM4E (0.56) | ALDH1A1LMNASMN1; SMN2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150557-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022202-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | EEF2K, VPS26B, VPS28 | ALDH1A1 4293/4885LMNA 4823/4885SMN1; SMN2 2885/4885 |
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | VPS26B, VPS4B, VPS28 | ALDH1A1 4381/4885LMNA 4810/4885SMN1; SMN2 3304/4885 |
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | ALDH1A1 4293/4885LMNA 4823/4885SMN1; SMN2 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.